Investigational Drug Information for INCB050465
✉ Email this page to a colleague
What is the drug development status for INCB050465?
INCB050465 is an investigational drug.
There have been 32 clinical trials for INCB050465.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 24th 2021.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and Mayo Clinic.
There are ten US patents protecting this investigational drug and two hundred and eighty-two international patents.
Summary for INCB050465
US Patents | 10 |
International Patents | 282 |
US Patent Applications | 61 |
WIPO Patent Applications | 38 |
Japanese Patent Applications | 8 |
Clinical Trial Progress | Phase 2 (2021-05-24) |
Vendors | 30 |
Recent Clinical Trials for INCB050465
Title | Sponsor | Phase |
---|---|---|
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | Incyte Corporation | Phase 3 |
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Incyte Corporation | Phase 3 |
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. | Chinese PLA General Hospital | Phase 2 |
Clinical Trial Summary for INCB050465
Top disease conditions for INCB050465
Top clinical trial sponsors for INCB050465
US Patents for INCB050465
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
INCB050465 | ⤷ Try a Trial | Bicyclic fused pyrimidine compounds as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
INCB050465 | ⤷ Try a Trial | Pyrrolopyrimidine derivatives as TAM inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
INCB050465 | ⤷ Try a Trial | Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
INCB050465 | ⤷ Try a Trial | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
INCB050465 | ⤷ Try a Trial | Salts and processes of preparing a PI3K inhibitor | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
INCB050465 | ⤷ Try a Trial | Heterocyclic compounds as PI3K-.gamma. inhibitors | Incyte Corporation (Wilmington, DE) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for INCB050465
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
INCB050465 | World Intellectual Property Organization (WIPO) | WO2017027717 | 2035-08-12 | ⤷ Try a Trial |
INCB050465 | World Intellectual Property Organization (WIPO) | WO2017035366 | 2035-08-26 | ⤷ Try a Trial |
INCB050465 | Australia | AU2015244044 | 2034-04-08 | ⤷ Try a Trial |
INCB050465 | Australia | AU2020213313 | 2034-04-08 | ⤷ Try a Trial |
INCB050465 | Australia | AU2022206693 | 2034-04-08 | ⤷ Try a Trial |
INCB050465 | Brazil | BR112016023322 | 2034-04-08 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |